Richmond Pharmacology continually evaluates the processes we undertake and examine whether they deliver maximum value to trial sponsors while not compromising quality or patient safety.

One of the ways we do this is through the use of adaptive trial protocols which enables the safe modification of a trial’s course in accordance with pre-specified rules in the protocol. Modifications may include for example, the need to change the patient sample size, review the data collected and evaluate which groups of patients are responding.

One of the reasons why the UK is an outstanding location to deliver clinical studies is that the regulator - the MHRA - embrace and support the use of adaptive trial protocols. This allows Contract Research Organisation’s such as us the ability to operate more flexibly and to take decisions faster; ensuring that trials can reach their end points sooner and the most promising therapeutics move to the next stage more quickly.

To read the full article, click here. If you would like to learn more about the value of adaptive protocols in clinical trials please contact us

Latest news

How Does Social Time Contribute to a Positive Workplace Culture?

March 13, 2023
Read the blog by Richmond Pharmacology’s Chair of the Social Committee and Head of Marketing, Elizabeth Romano about how being social improves organisational culture and embeds the core values.
Read more

Employee Well-Being: A Commitment that Defines Richmond

October 2, 2023
Dr. Junko Ono, the Occupational Support Manager at Richmond Pharmacology provides her insights on fostering a positive work environment.
Read more


ISA Symposium 2024

29-30 May 2024 
We will be attending the XIX International Symposium on Amyloidosis, taking place in Rochester, Minesota
View event